IGM Biosciences has pivoted from cancer therapeutics to autoimmune diseases despite setbacks, showing a 25% stock increase since last October. The company halted cancer trials, reduced its workforce, ...
MOUNTAIN VIEW, Calif., Sept. 30, 2024 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company creating and developing engineered IgM antibodies, today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results